BUZZ-Invivyd rises on late-stage trial testing COVID antibody against mRNA vaccines** Shares of drug developer Invivyd IVVD.O rise 5.17% to $1.83 premarket
** Co says it has launched a late-stage trial testing its experimental COVID antibody VYD2311 against mRNA vaccines
** Says study will enroll ~210 people and compare safety; adds that it will also test using the antibody and vaccines together
** Says FDA asked it to closely track heart inflammation, a rare side effect previously seen after mRNA vaccinations
** Adds VYD2311 is a single-shot antibody designed to protect against current COVID variants; uses same platform as IVVD drug that was cleared earlier
** Shares rose ~457% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments